{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 46,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 7,
  "notes": "Clinical trial safety reporting slide.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/40",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.85,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "list",
      "text": "No dose-limiting toxicities across dose levels 1-3\nAdverse events related to KT-253 and observed in at least 2 patients\nNausea (n=3): Grade 1 (n=2) and Grade 2 (n=1)\nDiarrhea (n=2): All Grade 1\nSerious adverse events (SAEs) deemed related to KT-253:\nHypotension (n=1): Grade 3, occurred during cycle 4\nDue to decreased oral intake; resolved with treatment including IV fluids\nPatient remains on study without dose reduction or recurrence of hypotension\nNo thrombocytopenia or neutropenia even after 6 cycles of KT-253",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4de25951-bba9-475c-8772-653862beff71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "As of October 20, 2023",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0b3ca63-b627-4bd7-8fa9-71dbf2cb01cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.44,
        "x": 0.28,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-253 Phase 1a: Safety Update",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7910d54-e378-4a81-935b-c6ddfce5ae3d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "43a5a907-738e-4348-b5dd-ca5c82bc85e2",
      "evidence": "list/bullet: No dose-limiting toxicities across dose levels 1-3",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 46,
      "from": 21,
      "beatId": "5b777767-ae99-4f1a-ab2a-67ed14bef3b5",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, highlighting upcoming milestones and events.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}